Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
复制标题
DOI：
10.1093/annonc/mdp411
复制
发表时间：
2010-05-01
影响因子：
50.5
通讯作者：
Escudier, B.
中科院分区：
文献类型：
--
作者：
Massard, C.;Zonierek, J.;Escudier, B.
患者和方法：在两个中心（Institut Gustave Escherosy，Villejuif，France，n = 85; Central Clinical Hospital of Military Medical Academy，Warsaw，波兰，n = 54）入组TARGET的患者组成了当前亚组，对随访期间脑转移的发生率进行了回顾性评价。治疗（索拉非尼与安慰剂）和脑转移瘤的发生之间的关联进行了评估，通过单变量analysis.Results：接受索拉非尼的患者脑转移瘤的总发生率为3%（2 70例患者）相比，12%（8 69例患者）在接受安慰剂（P < 0.05）。索拉非尼组治疗1年（P = 0.0447）和2年（P = 0.005）后脑转移瘤的发生率也显著低于安慰剂组（comparativeprotein.Conclusions）：在该亚群中，索拉非尼可减少脑转移瘤的发生。抗血管生成治疗，如索拉非尼，可能是一种有效的预防性治疗晚期肾癌脑转移。
Patients and methods: Patients enrolled in TARGET at two centres (Institut Gustave Roussy, Villejuif, France, n = 85; Central Clinical Hospital of Military Medical Academy, Warsaw, Poland, n = 54) made up the current subgroup, who were retrospectively evaluated for the incidence of brain metastases during follow-up. The association between treatment (sorafenib versus placebo) and occurrence of brain metastases was evaluated by univariate analysis.Results: The overall incidence of brain metastases in patients receiving sorafenib was 3% (2 of 70 patients) compared with 12% (8 of 69 patients) in patients receiving placebo (P < 0.05). The incidence of brain metastases was also significantly lower in the sorafenib group after 1 (P = 0.0447) and 2 years (P = 0.005) of treatment compared with the placebo group.Conclusions: In this subpopulation, sorafenib may reduce the occurrence of brain metastases. Antiangiogenic therapy, such as sorafenib, could be an effective preventive therapy for brain metastases in advanced RCC.